BioHarvest Sciences Inc. Quarterly Shareholder Update Live Event October 14, 2021, at 2:00pm E.T.

BioHarvest Sciences Inc. (CSE: BHSC) (FSE: 8MV) ("BioHarvest" or the "Company") invites its shareholders and the general public to join a Live Video Conference ("Webinar") on Thursday, October 14, 2021, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).

BioHarvest Sciences CEO Ilan Sobel will host the event, which will include a report on all major 2021 priorities, including a detailed performance update on the commercialization of the Company's two primary product verticals, Superfruit Nutraceuticals and Cannabis/Hemp.

"I am excited to share with you the details behind our 3^rd quarter strong performance," stated CEO Ilan Sobel. "On the update call, I will discuss the progress we have made this year, the foundational capabilities we have built, and the significant steps we will be taking towards the realization of our biotech vision."

The presentation will be approximately 45 minutes, followed by a live question and answer session. All shareholders, media, and interested investors are welcome to join. All registrants will be emailed a recording of the session.

Register at: https://app.livestorm.co/st-financial/october-2021-bhsc-shareholder-update?type=detailed

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6168/99293_61fcf644046a6a09_008full.jpg
Register Now

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/99293_61fcf644046a6a09_008full.jpg

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer
For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99293

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences CSE:BHSC Biotech Investing

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share (the "Offering Price") for gross proceeds of US$13.5 million (the "Offering"), Canaccord Genuity has purchased an additional 1,265,625 Common Shares at the Offering Price pursuant to their exercise in full of the over-allotment option (the "Over-Allotment Option"), for additional gross proceeds to the Company of $2,025,000 before deducting the underwriting commissions.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfully closed its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million, before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering.

As previously stated, the Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

BioHarvest Sciences Inc. Quarterly Shareholder Update Live Event October 14, 2021, at 2:00pm E.T.

1. Instil Bio (NASDAQ:TIL)

2. Rezolute Bio (NASDAQ:RZLT)

3. Candel Therapeutics (NASDAQ:CADL)

4. Benitec Biopharma (NASDAQ:BNTC)

5. Cardiol Therapeutics (NASDAQ:CRDL)

Latest News

Latest Press Releases

Related News

TOP STOCKS